#United States #New York #Wet AMD #REGENXBIO #Surabgene Lomparvovec

REGENXBIO to Host Investor Event on Surabgene Lomparvovec for Wet AMD

REGENXBIO Inc. (Nasdaq: RGNX) has announced that it will hold a significant investor event on October 20, 2026 at 1:00 p.m. ET. This occasion will focus on the clinical program surrounding surabgene lomparvovec (also known as Sura-vec) for the treatment of wet age-related macular degeneration (wet AMD). The event promises to illuminate the current treatment landscape and the unmet needs that patients face, particularly in the context of ongoing pivotal trials.

Overview of the Event

The event will take place in-person in New York, NY, with a virtual option available for those unable to attend physically. This hybrid format will allow a broader audience of investors, stakeholders, and interested parties to engage with the material presented.

The program will feature:

• - A comprehensive overview of the clinical program concerning Sura-vec.
• - Insights and perspectives from some of the leading retina specialists in the field, enhancing the understanding of the challenges and opportunities that lie ahead.
• - Discussions surrounding the ATMOSPHERE® and ASCENT® pivotal trials that are critical to the future development of this promising therapy.

Key opinion leaders expected to participate in the event include:

• - Gaurav Shah, M.D., from California Pacific Medical Center, Sutter Health.
• - Arshad Khanani, M.D., from Sierra Eye Associates.
• - Lejla Vajzovic, M.D., from Duke University School of Medicine.
• - Rahul Khurana, M.D., from the University of California at San Francisco.
• - Ramanath Bhandari, M.D., from Springfield Clinic Eye Institute.

Importance of Surabgene Lomparvovec

Surabgene lomparvovec represents a revolutionary approach to treating wet AMD, a leading cause of vision loss in elderly populations. By utilizing the advanced mechanism of gene therapy, this treatment aims to address the root causes of the disease rather than merely alleviating symptoms.

REGENXBIO is championing gene therapy advancements since its inception in 2009, focusing on developing one-time treatments for rare and retinal disorders. Sura-vec, which is being collaboratively developed with AbbVie, is a vital component of their late-stage pipeline, which also includes treatments for other serious conditions such as Duchenne Muscular Dystrophy and various types of Mucopolysaccharidosis.

Registration and Access

Those interested in attending the event are encouraged to register for the webcast via a link provided in REGENXBIO's official communications. For those unable to attend live, an archived replay will be made available in the investor's section of the company's website for approximately 30 days post-event.

Looking Ahead

With the topline pivotal data due to be released in the fourth quarter of 2026, this investor event stands as an essential platform for gathering crucial information on the efficacy and future of surabgene lomparvovec in altering the treatment paradigm of wet AMD. Stakeholders are eagerly awaiting insights that could reshape the healthcare framework for those grappling with this debilitating condition.

As always, REGENXBIO remains committed to improving patient outcomes through its innovative gene therapy solutions, aiming to transform the lives of patients across the globe.

For further information, visit REGENXBIO's official site.